Zhang Jinhua, Wang Wenjing, Guo Dingyi, Bai Baoqing, Bo Tao, Fan Sanhong
College of Life Sciences, Shanxi University, Taiyuan 030006, China.
Shanxi Key Laboratory of Research and Utilization of Characteristic Plant Resources, Shanxi University, Taiyuan 030006, China.
Foods. 2022 Oct 28;11(21):3406. doi: 10.3390/foods11213406.
Diabetes is a type of metabolic disease associated with changes in the intestinal flora. In this study, the regulatory effect of millet bran on intestinal microbiota in a model of type 2 diabetes (T2DM) was investigated in an effort to develop new approaches to prevent and treat diabetes and its complications in patients. The effect of purified millet bran polysaccharide (MBP) with three different intragastric doses (400 mg/kg, 200 mg/kg, and 100 mg/kg) combined with a high-fat diet was determined in a streptozotocin (STZ)-induced model of T2DM. By analyzing the changes in indicators, weight, fasting blood sugar, and other bio-physiological parameters, the changes in gut microbiota were analyzed via high-throughput sequencing to establish the effect of MBP on the intestinal flora. The results showed that MBP alleviated symptoms of high-fat diet-induced T2DM. A high dosage of MBP enhanced the hypoglycemic effects compared with low and medium dosages. During gavage, the fasting blood glucose (FBG) levels of rats in the MBP group were significantly reduced (p < 0.05). The glucose tolerance of rats in the MBP group was significantly improved (p < 0.05). In diabetic mice, MBP significantly increased the activities of CAT, SOD, and GSH-Px. The inflammatory symptoms of liver cells and islet cells in the MBP group were alleviated, and the anti-inflammatory effect was partially correlated with the dose of MBP. After 4 weeks of treatment with MBP, the indices of blood lipid in the MBP group were significantly improved compared with those of the DM group (p < 0.05). Treatment with MBP (400 mg/kg) increases the levels of beneficial bacteria and decreases harmful bacteria in the intestinal tract of rats, thus altering the intestinal microbial community and antidiabetic effect on mice with T2DM by modulating gut microbiota. The findings suggest that MBP is a potential pharmaceutical supplement for preventing and treating diabetes.
糖尿病是一种与肠道菌群变化相关的代谢性疾病。在本研究中，研究了小米麸皮对2型糖尿病（T2DM）模型中肠道微生物群的调节作用，以期开发预防和治疗糖尿病及其并发症患者的新方法。在链脲佐菌素（STZ）诱导的T2DM模型中，测定了三种不同胃内给药剂量（400mg/kg、200mg/kg和100mg/kg）的纯化小米麸皮多糖（MBP）与高脂饮食联合使用的效果。通过分析体重、空腹血糖等生物生理指标的变化，采用高通量测序分析肠道微生物群的变化，以确定MBP对肠道菌群的影响。结果表明，MBP减轻了高脂饮食诱导的T2DM症状。与低剂量和中剂量相比，高剂量的MBP增强了降血糖作用。灌胃期间，MBP组大鼠的空腹血糖（FBG）水平显著降低（p<0.05）。MBP组大鼠的糖耐量显著改善（p<0.05）。在糖尿病小鼠中，MBP显著提高了CAT、SOD和GSH-Px的活性。MBP组肝细胞和胰岛细胞的炎症症状减轻，抗炎作用与MBP剂量部分相关。MBP治疗4周后，MBP组的血脂指标与糖尿病组相比显著改善（p<0.05）。用MBP（400mg/kg）治疗可增加大鼠肠道内有益菌的水平，减少有害菌，从而改变肠道微生物群落，并通过调节肠道菌群对T2DM小鼠产生抗糖尿病作用。研究结果表明，MBP是一种预防和治疗糖尿病的潜在药物补充剂。
Zotero 插件
